Drawing for OLIGOSURF

USPTO serial 76113579

OLIGOSURF

Reviewed by CopyMark Law Group

Reg. 2655564Status 710
Filing date
Status date
Registration date
Dec 3, 2002
Examiner
MICHOS, JOHN E
Law office
SCANNING ON DEMAND

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with OLIGOSURF?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Dr. Viviana Amzel

DR VIVIANA AMZEL EPIGENESIS PHARMACEUTICALS, INC7 CLARKE DRCRANBURY, NJ 08512UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
042Describing and providing services for scientific and medical research services, namely, screening of oligonucleotide libraries to identify active anti-sense oligonucleotides for use in pharmaceutical preparations for administration via various routes, including respiratory airways, for testing and prophylaxis and therapeutic treatment of human and non-human animal ailments that may be associated with hyper-sensitivity or hyper-responsiveness to adenosine, including bronchoconstriction, difficult breathing, impeded and obstructed lung airways, allergy(ies) and/or inflammation, which in many cases are adenosine receptor associated symptoms, particularly testing, preventing and therapeutically treating respiratory, airway, pulmonary and other diseases and conditions, such as asthma, pulmonary vasoconstriction, inflammation, allergies, asthma; impeded respiration, Acute Respiratory Distress Syndrome (ARDS), renal damage and failure, ischemia, administration of certain drugs, including adenosine and other drugs for, for example, treating SupraVentricular Tachycardia (SVT), adenosine stress tests, infantile Respiratory Distress Syndrome (infantile RDS), pain, cystic fibrosis, allergic rhinitis, ___ bronchitis, pulmonary hypertension, pulmonary vasoconstriction, emphysema, chronic obstructive pulmonary disease (COPD), as well as cancers including leukemias, lymphomas, carcinomas, and the like, e.g. colon cancer, breast cancer, lung cancer, pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma, hepatic metastases, etc., as well as all other metastatic cancers, e.g. cancers which metastasized to the lung(s), breast and prostateSECTION 8 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jul 11, 2009C8..CANCELLED SEC. 8 (6-YR)—
Jan 23, 2008CFITCASE FILE IN TICRS—
May 24, 2006ASCKASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY—
Dec 3, 2002R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Sep 10, 2002PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 21, 2002NPUBNOTICE OF PUBLICATION—
Oct 25, 2001CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 10, 2001CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 7, 2001CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 1, 2001DOCKASSIGNED TO EXAMINER—
Jan 31, 2001DOCKASSIGNED TO EXAMINER—

Frequently asked questions

Related guidance